来瑞特韦在重度肾功能不全患者中的耐受性与药代动力学
本研究比较来瑞特韦在重度肾功能不全患者(n=7)与健康对照(n=8)中的药代动力学与安全性。结果显示肾功能不全组Cmax、AUC0-t、AUC0-∞分别增加30.34%、54.19%、56.83%,但治疗指数宽,药代改变临床意义不大,无需调整剂量。
要点
- 重度肾功能不全患者来瑞特韦暴露量增加,但无需调整剂量。
- 来瑞特韦耐受性良好,不良事件多为轻中度且持续时间短。
- 药代改变在宽治疗指数下临床意义不显著。
核心结论
- 重度肾功能不全患者来瑞特韦药代动力学有轻度改变,但临床意义不显著,无需调整剂量。
研究设计与样本
- 非随机、开放标签、平行组、单次给药试验,纳入重度肾功能不全患者7例和健康对照8例。
主要发现
- 重度肾功能不全组与健康对照组中位Tmax相似,但消除半衰期较短(4.20 h vs. 5.09 h)。
- 重度肾功能不全组Cmax、AUC0-t、AUC0-∞的几何均值比(90%CI)分别增加30.34%、54.19%、56.83%。
- 不良事件为轻中度且持续时间短,来瑞特韦耐受性良好。
关键数值与推荐
- 主要药代终点包括Cmax、AUC0-t、AUC0-∞、t1/2;安全性终点包括不良事件、生命体征、实验室检查。
- 对数转换后的药代参数采用方差分析计算几何均值比(90%置信区间)进行组间比较。
临床怎么用
- 重度肾功能不全患者使用来瑞特韦无需调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The study's aim is to evaluate the pharmacokinetics (PK) and safety of leritrelvir, a novel 3-chymotrypsin-like cysteine protease (3CLpro) inhibitor, in patients with severe renal impairment (RI; n = 7) compared to healthy controls (n = 8). METHODS: This nonrandomized, open-label, parallel-group, single-dose trial included primary PK endpoints (Cmax, AUC0-t, AUC0-∞, t1/2) and safety endpoints (AEs, vital signs, laboratory tests). Log-transformed PK parameters were analysed by ANOVA to calculate GMRs (90% confidence intervals [CIs]) for group comparisons, with statistical significance assessed for exposure differences. RESULTS: PK analysis revealed similar median time-to-peak concentration (Tmax) but a reduced elimination half-life (t1/2) in the RI group (4.20 h vs. 5.09 h). The geometric mean ratios (90% CI) of systemic exposure parameters indicated increases of 30.34% for Cmax, 54.19% for AUC0-t, and 56.83% for AUC0-∞ in the RI group compared to controls. CONCLUSIONS: Modest PK alterations in severe renal impairment are clinically insignificant given leritrelvir's wide therapeutic index. The drug is well-tolerated (mild-to-moderate, short-duration AEs), and no dose adjustment is needed for patients with renal impairment.
引用
- Zhou ZY, Wen XQ, Zhang WR, et al. Tolerability and pharmacokinetics of leritrelvir in Chinese participants with severe renal impairment and healthy matched control subjects. Br J Clin Pharmacol. 2026. PMID: 41617220. doi:10.1002/bcp.70474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。